News
Zhejiang Provincial Commission of Economy and Information Director Zhang Jinru and his delegation visited Wanbangde Group for an inspection.
Date:
01 Mar,2021
On the morning of February 15, Zhang Jinru, Director of the Zhejiang Provincial Commission of Economy and Information Technology, along with Jia Fan, Director of the Commission’s Operations Division, and other members of their delegation, conducted an in-depth inspection of Wanbangde Group. Accompanied by Li Yuecheng, Vice Mayor of Taizhou City; Guo Sijia, Deputy Secretary-General of the Taizhou Municipal Government; Lin Dinggang, Director of the Taizhou Commission of Economy and Information Technology; and Wang Zongming, Acting Mayor of Wenling City, the delegation explored how private enterprises in the region could leverage the opportunities presented by the national-level 13th Five-Year Plan to achieve leapfrog development, as well as initiatives related to the construction of distinctive small towns. Zhao Shouming, Chairman of Wanbangde Group, welcomed Director Zhang Jinru and his delegation.
During the inspection, Director Zhang Jinru and his delegation toured the group’s product showroom and the sandbox model of Wenling Medical & Healthcare Town. They engaged Chairman Zhao Shouming in a detailed discussion, gaining insights into the core products of each of the group’s key industries. In the subsequent meeting, Chairman Zhao Shouming first outlined the development journey of Wanbangde Group’s three major industries, shared the company’s operational performance from last year, and presented this year’s growth objectives to provincial and municipal leaders. He then reported on the remarkable achievements Wanbangde Group attained over the past year, highlighting four key areas: First, the group’s pharmaceutical division successfully completed the establishment of its market distribution network for its flagship product, Ginkgo Biloba Dropping Pills, in 2016, fully implementing the “two-invoice system” across its operations. Additionally, the company invested 32 million yuan in collaboration with the academic team led by Academician Tang Xican from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, to jointly develop the world’s first-ever sustained-release Huperzine A tablets—laying a robust foundation for the group’s next phase of rapid, transformative growth. Second, in advancing its medical device business, the group strategically acquired controlling stakes in five domestic and international medical equipment manufacturers last year. Moreover, it introduced cutting-edge orthopedic device technology from South Africa, effectively completing the group’s global expansion into the healthcare sector. Third, to accelerate the pharmaceutical division’s entry into the capital markets, the group finalized its acquisition of actual controlling interest in Huzhou Dongliang New Materials Co., Ltd. Finally, Wanbangde Group signed a cooperation framework agreement with the Wenling Municipal Government to jointly develop the Wenling Medical & Healthcare Town. Under this initiative, the group plans to invest a total of 5.35 billion yuan to build 18 landmark projects, creating a comprehensive, full-chain health-focused town that aims to become a pioneering national benchmark in the healthcare industry.
Director Zhang Jinru, after listening to Chairman Zhao Shouming’s report, emphasized that Wengling-based enterprises must leverage their unique characteristics, clearly identify the group’s core strengths, and align their development strategies with both the global economic landscape and the ongoing trend of industrial upgrading in China. He urged them to drive technological innovation, deepen corporate transformation and upgrades, and ultimately foster the rapid, healthy growth of Zhejiang’s non-public sector economy during the ambitious 13th Five-Year Plan period.
The second from the right is Director Zhang Jinru.
Related Recommendations